Also, recently Natu et al. showed that long-term sustained delivery was achieved using implantable disks prepared based on PCL disks loaded with dorzolamide administered through subconjunctival implantation in rabbit eyes. The disks were well tolerated in vivo and histological analysis of tissues from the target site indicated normal foreign body reaction suggesting that the implanted disks were biocompatible [33]. Effective IOP lowering effect was obtained Carfilzomib Phase 2 compared to topically applied dorzolamide suggesting improved bioavailability of drug using biodegradable disks. Further to the aforementioned studies on biodegradable ocular implants, there are number of clinically available Inhibitors,research,lifescience,medical ocular implants

that may be adapted in developing intravitreal drug delivery platforms in glaucoma. A notable example is Ozurdex (Allergan, Irvine, CA), which is a biodegradable rod-shaped dexamethasone implant approved by the FDA for intravitreal ocular implantation in the treatment of macular Inhibitors,research,lifescience,medical edema and selleck chemicals uveitis affecting the posterior segment of the eye [49]. A recently conducted clinical trial on safety and efficacy of delivering brimonidine using Ozurdex PLGA platform [50] is a demonstration that the Ozurdex platform could be applied in intravitreal delivery of neuroprotective agents in glaucoma. 2.2.2. Nonbiodegradable Ocular Implants Many nonbiodegradable

polymers have been applied Inhibitors,research,lifescience,medical in making implants that can provide long-term, controlled release of a variety of drugs/therapeutics. These include polyvinyl alcohol (PVA), ethylene vinyl acetate (EVA), and silicone [51–53]. The major disadvantages with these systems are (1) the need for surgical procedure to remove the device from the site of implantation once the drug is completely released; (2) prolonged intraocular Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical placement of the delivery systems could potentially

trigger immune responses. In spite of the potential shortcomings, nonbiodegradable implants are less likely to produce burst drug release as compared to biodegradable ones. Ability to achieve predictable and linear drug release kinetics is desirable for prolonged drug action [46, 54, 55]. We are of the opinion that a number of nonbiodegradable ocular devices that are approved for intravitreal drug delivery in other ocular diseases could be adapted in glaucoma management. These include (i) AV-951 Vitrasert, an intravitreal implantable reservoir system by Bausch & Lomb (Rochester, NY), approved for cytomegalovirus (CMV) retinitis. The implant is composed of PVA-EVA for delivery of ganciclovir over a period of 5 to 8 months [56, 57]; (ii) Retisert is similar in shape to Vitrasert is composed of PVA, silicone laminate, and is FDA approved for chronic noninfectious uveitis. This intravitreal surgical implant is designed to release corticosteroid fluocinolone acetonide in a sustained manner directly in the vitreous for about 2.5 years [58, 59].